PMID- 28476786
OWN - NLM
STAT- MEDLINE
DCOM- 20170810
LR  - 20170810
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 37
IP  - 5
DP  - 2017 May
TI  - Amphiregulin as a Novel Resistance Factor for Amrubicin in Lung Cancer Cells.
PG  - 2225-2231
AB  - BACKGROUND/AIM: Amrubicin (AMR) has shown promising activity for lung cancer. 
      However, little is known about the mechanism underlying resistance to this agent. 
      The aim of this study was to elucidate the mechanism underlying resistance to 
      AMR. MATERIALS AND METHODS: We first developed amrubicinol (AMR-OH)-resistant 
      cell lines (H520/R and DMS53/R) by exposing lung cancer cell lines (H520 and 
      DMS53) to increasing concentrations of AMR-OH and performed functional analysis 
      by using these cell lines. RESULTS: Transcriptome analyses showed that 
      amphiregulin (AREG) was the most highly up-regulated gene in both 
      AMR-OH-resistant cell lines compared to parent cells. Conditioned medium from 
      DMS53/R cells reduced the sensitivity to AMR-OH in DMS53 cells. In contrast, 
      DMS53/R cells transfected with siRNA directed against AREG recovered their 
      sensitivity to AMR-OH. An additional administration of cetuximab with amrubicinol 
      also restored the sensitivity to AMR-OH. CONCLUSION: Amphiregulin plays an 
      important role in resistance to AMR-OH.
CI  - Copyright(c) 2017, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Tokunaga, Shuntaro
AU  - Tokunaga S
AD  - Division of Respiratory Medicine, Department of Internal Medicine, Kobe 
      University Graduate School of Medicine, Kobe, Japan.
FAU - Nagano, Tatsuya
AU  - Nagano T
AD  - Division of Respiratory Medicine, Department of Internal Medicine, Kobe 
      University Graduate School of Medicine, Kobe, Japan tnagano@med.kobe-u.ac.jp.
FAU - Kobayashi, Kazuyuki
AU  - Kobayashi K
AD  - Division of Respiratory Medicine, Department of Internal Medicine, Kobe 
      University Graduate School of Medicine, Kobe, Japan.
FAU - Katsurada, Masahiro
AU  - Katsurada M
AD  - Division of Respiratory Medicine, Department of Internal Medicine, Kobe 
      University Graduate School of Medicine, Kobe, Japan.
FAU - Nakata, Kyosuke
AU  - Nakata K
AD  - Division of Respiratory Medicine, Department of Internal Medicine, Kobe 
      University Graduate School of Medicine, Kobe, Japan.
FAU - Yamamoto, Masatsugu
AU  - Yamamoto M
AD  - Division of Respiratory Medicine, Department of Internal Medicine, Kobe 
      University Graduate School of Medicine, Kobe, Japan.
FAU - Tachihara, Motoko
AU  - Tachihara M
AD  - Division of Respiratory Medicine, Department of Internal Medicine, Kobe 
      University Graduate School of Medicine, Kobe, Japan.
FAU - Kamiryo, Hiroshi
AU  - Kamiryo H
AD  - Division of Respiratory Medicine, Department of Internal Medicine, Kobe 
      University Graduate School of Medicine, Kobe, Japan.
FAU - Yokozaki, Hiroshi
AU  - Yokozaki H
AD  - Division of Pathology, Department of Pathology, Kobe University Graduate School 
      of Medicine, Kobe, Japan.
FAU - Nishimura, Yoshihiro
AU  - Nishimura Y
AD  - Division of Respiratory Medicine, Department of Internal Medicine, Kobe 
      University Graduate School of Medicine, Kobe, Japan.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Amphiregulin)
RN  - 0 (Anthracyclines)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (RNA, Small Interfering)
RN  - 0 (amrubicinol)
RN  - 93N13LB4Z2 (amrubicin)
SB  - IM
MH  - Amphiregulin/*genetics
MH  - Animals
MH  - Anthracyclines/*pharmacology/therapeutic use
MH  - Antineoplastic Agents/*pharmacology/therapeutic use
MH  - Cell Line, Tumor
MH  - Drug Resistance, Neoplasm/*genetics
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/drug therapy/*genetics/pathology
MH  - Mice, Inbred BALB C
MH  - Mice, Nude
MH  - RNA, Small Interfering
MH  - Tumor Burden/drug effects
OTO - NOTNLM
OT  - Amrubicin
OT  - amphiregulin
OT  - cetuximab
OT  - lung cancer
EDAT- 2017/05/10 06:00
MHDA- 2017/08/11 06:00
CRDT- 2017/05/07 06:00
PHST- 2017/03/22 00:00 [received]
PHST- 2017/04/01 00:00 [revised]
PHST- 2017/04/03 00:00 [accepted]
PHST- 2017/05/07 06:00 [entrez]
PHST- 2017/05/10 06:00 [pubmed]
PHST- 2017/08/11 06:00 [medline]
AID - 37/5/2225 [pii]
AID - 10.21873/anticanres.11558 [doi]
PST - ppublish
SO  - Anticancer Res. 2017 May;37(5):2225-2231. doi: 10.21873/anticanres.11558.